
News|Articles|November 1, 2024
AAV Production in Culture Biosciences’ 250mL Bioreactors
Author(s)Culture Biosciences
Adeno-associated virus (AAV) is a critical vector in gene therapy, but process robustness and scalability can pose challenges. This whitepaper demonstrates how Culture Biosciences' on-demand fleets of 250mL bioreactors enable large-scale experimentation and real-time data access to optimize upstream processes. Learn how process optimization can increase the fraction of full AAV capsids, accelerating your path to market.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
